GCP
ADPT icon

GSA Capital Partners’s Adaptive Biotechnologies ADPT Stock Holding History

GSA Capital Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-48,165
Closed -$247K – 1565
2024
Q3 		$247K Buy
+48,165
New +$210K 0.02% 1324
2023
Q2 		– Sell
-133,396
Closed -$1.18M – 1467
2023
Q1 		$1.18M Buy
133,396
+42,793
+47% +$377K 0.12% 238
2022
Q4 		$692K Buy
90,603
+61,901
+216% +$482K 0.09% 407
2022
Q3 		$204K Buy
28,702
+4,457
+18% +$42K 0.03% 1216
2022
Q2 		$196K Buy
+24,245
New +$213K 0.03% 1074
2022
Q1 		– Sell
-7,485
Closed -$210K – 1365
2021
Q4 		$210K Buy
+7,485
New +$229K 0.03% 1182
2019
Q3 		– Sell
-6,000
Closed -$290K – 1357
2019
Q2 		$290K Buy
+6,000
New +$266K 0.03% 1021

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

GSA Capital Partners's ADPT Position: Q4 2024 in Review

GSA Capital Partners sold out of Adaptive Biotechnologies (ADPT) in Q4 2024, closing a stake of 48,165 shares — an estimated $247K sold.

GSA Capital Partners first reported a position in ADPT in Q2 2019 and held it in 7 quarters. The position peaked at $1.18M in Q1 2023. 207 funds tracked by Wall St. Rank hold ADPT as of Q4 2024.

  • GSA Capital Partners reported no remaining Adaptive Biotechnologies position as of Q4 2024 after selling out during the quarter.
  • GSA Capital Partners sold 48,165 Adaptive Biotechnologies shares in Q4 2024, an estimated $247K.
  • GSA Capital Partners first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 7 quarters.
  • GSA Capital Partners's Adaptive Biotechnologies position peaked at $1.18M in Q1 2023.
  • 207 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2024.

Based on GSA Capital Partners's 13F filing for Q4 2024, filed 7 Feb 2025.